National Heart, Lung, and Blood Institute; Notice of Meeting, 11925-11926 [2017-03706]

Download as PDF Federal Register / Vol. 82, No. 37 / Monday, February 27, 2017 / Notices would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; NHLBI Clinical Trial Pilot Studies (R34). Date: March 17, 2017. Time: 8:30 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: YingYing Li-Smerin, MD, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 7184, Bethesda, MD 20892– 7924, 301–827–7942, lismerin@nhlbi.nih.gov. Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; Collaborative Projects in Organ Fibrosis. Date: March 21, 2017. Time: 8:30 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Courtyard by Marriott, 5520 Wisconsin Avenue, Chevy Chase, MD 20815. Contact Person: Kristen Page, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, National Institutes of Health, 6701 Rockledge Drive, Room 7185, Bethesda, MD 20892, 301–827–7953, kristen.page@ nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS) Dated: February 21, 2017. Michelle Trout, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2017–03704 Filed 2–24–17; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health mstockstill on DSK3G9T082PROD with NOTICES National Library of Medicine; Notice of Meeting Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App), notice is hereby given of a meeting of the Board of Scientific Counselors, National Center for Biotechnology Information. The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. VerDate Sep<11>2014 20:23 Feb 24, 2017 Jkt 241001 The meeting will be closed to the public as indicated below in accordance with the provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended for review, discussion, and evaluation of individual intramural programs and projects conducted by the NATIONAL LIBRARY OF MEDICINE, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Board of Scientific Counselors, National Center for Biotechnology Information. Date: May 2, 2017. Open: 8:30 a.m. to 12:00 p.m. Agenda: Program Discussion. Place: National Library of Medicine, Building 38, 2nd Floor, The Lindberg Room, 8600 Rockville Pike, Bethesda, MD 20892. Closed: 12:00 p.m. to 2:00 p.m. Agenda: To review and evaluate personal qualifications and performance, and competence of individual investigators. Place: National Library of Medicine, Building 38, 2nd Floor, The Lindberg Room, 8600 Rockville Pike, Bethesda, MD 20892. Open: 2:00 p.m. to 3:00 p.m. Agenda: Program Discussion. Place: National Library of Medicine, Building 38, 2nd Floor, The Lindberg Room, 8600 Rockville Pike, Bethesda, MD 20892. Contact Person: David J. Lipman, MD, Director, National Center for Biotechnology Information, National Library of Medicine, Building 38A, Room 8N805, Bethesda, MD 20892, 301–435–5985, dlipman@ mail.nih.gov. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver’s license, or passport) and to state the purpose of their visit. (Catalogue of Federal Domestic Assistance Program No. 93.879, Medical Library Assistance, National Institutes of Health, HHS) Dated: February 21, 2017. Michelle Trout, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2017–03702 Filed 2–24–17; 8:45 am] BILLING CODE 4140–01–P PO 00000 Frm 00035 Fmt 4703 Sfmt 4703 11925 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of General Medical Sciences; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of General Medical Sciences Special Emphasis Panel Review of U54 Application. Date: March 30, 2017. Time: 8:30 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Hilton Garden Inn Bethesda, 7301 Waverly Street, Bethesda, MD 20814. Contact Person: Lisa A. Dunbar, Scientific Review Officer, Office of Scientific Review, National Institute of General Medical Sciences, National Institutes of Health, 45 Center Drive, Room 3AN12, Bethesda, MD 20892, 301–594–2849, dunbarl@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.375, Minority Biomedical Research Support; 93.821, Cell Biology and Biophysics Research; 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.862, Genetics and Developmental Biology Research; 93.88, Minority Access to Research Careers; 93.96, Special Minority Initiatives; 93.859, Biomedical Research and Research Training, National Institutes of Health, HHS) Dated: February 22, 2017. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2017–03822 Filed 2–24–17; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Heart, Lung, and Blood Institute; Notice of Meeting Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the Sickle Cell Disease Advisory Committee. E:\FR\FM\27FEN1.SGM 27FEN1 11926 Federal Register / Vol. 82, No. 37 / Monday, February 27, 2017 / Notices The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. Name of Committee: Sickle Cell Disease Advisory Committee. Date: March 29, 2017. Time: 8:30 a.m. to 1:45 p.m. Agenda: Presentations and Discussion of Training the Next Generation of Researchers in Sickle Cell Disease. Place: National Institutes of Health 6701 Rockledge Drive, 9th Floor, Room 9100/9104, Bethesda, MD 20892. Contact Person: W. Keith Hoots, MD, Director, Division of Blood Diseases and Resources, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Suite 9030, Bethesda, MD 20892, 301–435–0080, hootswk@nhlbi.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS) Dated: February 21, 2017. Michelle Trout, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2017–03706 Filed 2–24–17; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of Exclusive Patent License: The Development of an AntiMesothelin Recombinant Immunotoxin (RIT) for the Treatment of Human Cancers. AGENCY: National Institutes of Health, HHS. ACTION: Notice. The National Cancer Institute, National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to Selecta Biosciences (‘‘Selecta’’) located in Watertown, Massachusetts to practice the inventions embodied in the patent applications listed in the SUPPLEMENTARY INFORMATION section of this notice. DATES: Only written comments and/or applications for a license which are received by the NCI Technology Transfer Center on or before March 14, 2017 will be considered. mstockstill on DSK3G9T082PROD with NOTICES SUMMARY: VerDate Sep<11>2014 20:23 Feb 24, 2017 Jkt 241001 Requests for copies of the patent applications, inquiries, and comments relating to the contemplated Exclusive Patent License should be directed to: David A. Lambertson, Ph.D., Senior Licensing and Patenting Manager, NCI Technology Transfer Center, 9609 Medical Center Drive, RM 1E530 MSC 9702, Bethesda, MD 20892– 9702 (for business mail), Rockville, MD 20850–9702 Telephone: (240)–276– 6467; Email: lambertsond@mail.nih.gov. SUPPLEMENTARY INFORMATION: The following represents the intellectual property to be licensed under the prospective agreement: ADDRESSES: U.S. Patent Application 61/535,668 (HHS Ref. E–263–2011/0–US–01), PCT Application PCT/US2012/055034 (HHS reference E–263–2011/0–PCT–02), Australian Patent Application 2012308591 (HHS reference E–263–2011/0–AU–03), Canadian Patent Application 2846608 (HHS reference E–263–2011/0–CA–04), European Patent Application 12766780.6 (HHS reference E–263–2011/0–EP–05), US Patent 9,206,240 (HHS reference E–263– 2011/0–US–06), Hong Kong Patent Application 14111650.2 (HHS reference E– 263–2011/0–HK–07), and US Patent Application 14/927,645 (HHS reference E– 263–2011/0–US–08); U.S. Patent Application 61/495,085 (HHS Ref. E–174–2011/0–US–01), PCT Application PCT/US2012/041234 (HHS reference E–174–2011/0–PCT–02), Australian Patent Application 2012268013 (HHS reference E–174–2011/0–AU–03), Brazilian Patent Application 112013031262–9 (HHS reference E–174– 2011/0–BR–04), Canadian Patent Application 2838013 (HHS reference E– 174–2011/0–CA–05), Chinese Patent Application 201280039071.1 (HHS reference E–174–2011/0–CN–06), European Patent Application 12727074.2 (HHS reference E–174–2011/0–EP–07), Hong Kong Patent Application 14105911.9 (HHS reference E–174–2011/0–HK–08), Japanese Patent Application 2014–514616 (HHS reference E–174–2011/0–JP–09), South Korean Patent Application 2013–7032402 (HHS reference E–174–2011/0–KR–10), Mexican Patent Application MX/a/2013/ 014388 (HHS reference E–174–2011/0– MX–11), Russian Patent Application 2013151655 (HHS reference E–174–2011/ 0–RU–12), US Patent 9,346,859 (HHS reference E–174–2011/0–US–13), Hong Kong Patent Application 14106689.7 (HHS reference E–174–2011/0–HK–14), and US Patent Application 15/095,470 (HHS reference E–174–2011/0–US–15); U.S. Patent Application 61/483,531 (HHS Ref. E–117–2011/0–US–01), PCT Application PCT/US2012/036456 (HHS reference E–117–2011/0–PCT–02), Australian Patent Application 2012253896 (HHS reference E–117–2011/0–AU–03), Brazilian Patent Application 112013028537–0 (HHS reference E–117– 2011/0–BR–04), Canadian Patent Application 2835070 (HHS reference E– 117–2011/0–CA–05), Chilean Patent PO 00000 Frm 00036 Fmt 4703 Sfmt 4703 Application 03182–2013 (HHS reference E–117–2011/0–CL–06), Ecuadorian Patent Application SP–13–13067 (HHS reference E–117–2011/0–EC–07), Egyptian Patent Application PCT 1697/2013 (HHS reference E–117–2011/0–EG–08), European Patent Application 12722586.0 (HHS reference E–117–2011/0–EP–09), Hong Kong Patent Application 14105586.3 (HHS reference E–117–2011/0–HK–10), South Korean Patent Application 2013–7032247 (HHS reference E–117–2011/0–KR–11), Mexican Patent Application MX/a/2013/ 012905 (HHS reference E–117–2011/0– MX–12), Malaysian Patent Application PI2013702094 (HHS reference E–117– 2011/0–MY–13), New Zealand Patent Application 617386 (HHS reference E– 117–2011/0–NZ–14), Philippines Patent Application 1–2013–502264 (HHS reference E–117–2011/0–PH–15), Russian Patent Application 2013148919 (HHS reference E–117–2011/0–RU–16), Singapore Patent Application 201308179– 9 (HHS reference E–117–2011/0–SG–17), Thailand Patent Application 1301006329 (HHS reference E–117–2011/0–TH–18), Ukrainian Patent Application 201313011 (HHS reference E–117–2011/0–UA–19), Vietnamese Patent Application 1–2013– 03855 (HHS reference E–117–2011/0–VN– 20), South African Patent Application 2013/08270 (HHS reference E–117–2011/ 0–ZA–21), US Patent Application 14/ 115,131 (HHS reference E–117–2011/0– US–22), Japanese Patent Application 2014– 509467 (HHS reference E–117–2011/0–JP– 23), Chinese Patent 201280033583.7 (HHS reference E–117–2011/0–CN–24), Colombian Patent Application 13–274.153 (HHS reference E–117–2011/0–CO–25), Costa Rican Patent Application 2013–0571 (HHS reference E–117–2011/0–CR–26), Indonesian Patent Application W– 00201305198 (HHS reference E–117–2011/ 0–ID–27), Israeli Patent Application 229198 (HHS reference E–117–2011/0–IL– 28), Indian Patent Application 8854/ CHENP/2013 (HHS reference E–117–2011/ 0–IN–29), Peruvian Patent Application 2456.13 (HHS reference E–117–2011/0– PE–30), Algerian Patent Application 130758 (HHS reference E–117–2011/0–DZ– 31), Moroccan Patent Application 36534 (HHS reference E–117–2011/0–MA–32), and Hong Kong Patent Application 14108273.5 (HHS reference E–117–2011/0– HK–33); U.S. Patent Application 61/241,620 (HHS Ref. E–269–2009/0–US–01), PCT Application PCT/US2010/048504 (HHS reference E–269–2009/0–PCT–02), Australian Patent 2010292069 (HHS reference E–269–2009/0–AU–03), Canadian Patent Application 2773665 (HHS reference E–269–2009/0–CA–04), Chinese Patent 201080049559.3 (HHS reference E–269–2009/0–CN–05), European Patent 2475398 (HHS reference E–269– 2009/0–EP–06), as validated in France, Germany, Italy, Spain and the United Kingdom, Indian Patent Application 3197/ CHENP/2012 (HHS reference E–269–2009/ 0–IN–07), Japanese Patent 5795765 (HHS reference E–269–2009/0–JP–08), Russian Patent Application 2012114005 (HHS E:\FR\FM\27FEN1.SGM 27FEN1

Agencies

[Federal Register Volume 82, Number 37 (Monday, February 27, 2017)]
[Notices]
[Pages 11925-11926]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-03706]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Heart, Lung, and Blood Institute; Notice of Meeting

    Pursuant to section 10(a) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of a meeting of the 
Sickle Cell Disease Advisory Committee.

[[Page 11926]]

    The meeting will be open to the public, with attendance limited to 
space available. Individuals who plan to attend and need special 
assistance, such as sign language interpretation or other reasonable 
accommodations, should notify the Contact Person listed below in 
advance of the meeting.

    Name of Committee: Sickle Cell Disease Advisory Committee.
    Date: March 29, 2017.
    Time: 8:30 a.m. to 1:45 p.m.
    Agenda: Presentations and Discussion of Training the Next 
Generation of Researchers in Sickle Cell Disease.
    Place: National Institutes of Health 6701 Rockledge Drive, 9th 
Floor, Room 9100/9104, Bethesda, MD 20892.
    Contact Person: W. Keith Hoots, MD, Director, Division of Blood 
Diseases and Resources, National Heart, Lung, and Blood Institute, 
6701 Rockledge Drive, Suite 9030, Bethesda, MD 20892, 301-435-0080, 
hootswk@nhlbi.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, 
National Center for Sleep Disorders Research; 93.837, Heart and 
Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, 
Blood Diseases and Resources Research, National Institutes of 
Health, HHS)

    Dated: February 21, 2017.
Michelle Trout,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-03706 Filed 2-24-17; 8:45 am]
 BILLING CODE 4140-01-P